Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.

Aldinucci D, Borghese C, Casagrande N.

Int J Mol Sci. 2019 May 15;20(10). pii: E2416. doi: 10.3390/ijms20102416. Review.

2.

Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives.

Altaf M, Casagrande N, Mariotto E, Baig N, Kawde AN, Corona G, Larcher R, Borghese C, Pavan C, Seliman AA, Aldinucci D, Isab AA.

Cancers (Basel). 2019 Apr 4;11(4). pii: E474. doi: 10.3390/cancers11040474.

3.

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.

Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D.

Haematologica. 2019 Mar;104(3):564-575. doi: 10.3324/haematol.2018.196725. Epub 2018 Oct 11.

4.

Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.

Aldinucci D, Casagrande N.

Int J Mol Sci. 2018 May 16;19(5). pii: E1477. doi: 10.3390/ijms19051477. Review.

5.

Improved GMP compliant approach to manipulate lipoaspirates, to cryopreserve stromal vascular fraction, and to expand adipose stem cells in xeno-free media.

Agostini F, Rossi FM, Aldinucci D, Battiston M, Lombardi E, Zanolin S, Massarut S, Parodi PC, Da Ponte A, Tessitori G, Pivetta B, Durante C, Mazzucato M.

Stem Cell Res Ther. 2018 May 11;9(1):130. doi: 10.1186/s13287-018-0886-1.

6.

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P.

Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29.

7.

Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.

Borghese C, Casagrande N, Pivetta E, Colombatti A, Boccellino M, Amler E, Normanno N, Caraglia M, De Rosa G, Aldinucci D.

Oncotarget. 2017 Jun 27;8(26):42926-42938. doi: 10.18632/oncotarget.17216.

8.

New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status.

Altaf M, Monim-Ul-Mehboob M, Kawde AN, Corona G, Larcher R, Ogasawara M, Casagrande N, Celegato M, Borghese C, Siddik ZH, Aldinucci D, Isab AA.

Oncotarget. 2017 Jan 3;8(1):490-505. doi: 10.18632/oncotarget.13448.

9.

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.

Aldinucci D, Celegato M, Casagrande N.

Cancer Lett. 2016 Sep 28;380(1):243-52. doi: 10.1016/j.canlet.2015.10.007. Epub 2015 Oct 23. Review.

PMID:
26474544
10.

Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.

Celegato M, Borghese C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, Spina M, Colombatti A, Aldinucci D.

Blood. 2015 Sep 10;126(11):1394-7. doi: 10.1182/blood-2015-07-660365. Epub 2015 Jul 30. No abstract available.

11.

Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.

Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Clin Cancer Res. 2014 Nov 1;20(21):5496-506. doi: 10.1158/1078-0432.CCR-14-0713. Epub 2014 Sep 17.

12.

Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts.

Celegato M, Fregona D, Mongiat M, Ronconi L, Borghese C, Canzonieri V, Casagrande N, Nardon C, Colombatti A, Aldinucci D.

Future Med Chem. 2014 Jul;6(11):1249-63. doi: 10.4155/fmc.14.81.

PMID:
25162999
13.

The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.

Celegato M, Borghese C, Umezawa K, Casagrande N, Colombatti A, Carbone A, Aldinucci D.

Cancer Lett. 2014 Jul 10;349(1):26-34. doi: 10.1016/j.canlet.2014.03.030. Epub 2014 Apr 2.

PMID:
24704296
14.

The inflammatory chemokine CCL5 and cancer progression.

Aldinucci D, Colombatti A.

Mediators Inflamm. 2014;2014:292376. doi: 10.1155/2014/292376. Epub 2014 Jan 2. Review.

15.

Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.

Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Gynecol Oncol. 2013 Dec;131(3):744-52. doi: 10.1016/j.ygyno.2013.08.041. Epub 2013 Sep 10.

PMID:
24029417
16.

Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.

Celegato M, Borghese C, Casagrande N, Carbone A, Colombatti A, Aldinucci D.

Leuk Lymphoma. 2014 Jan;55(1):149-59. doi: 10.3109/10428194.2013.800196. Epub 2013 Jun 12.

PMID:
23647062
17.

Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.

Borghese C, Cattaruzza L, Pivetta E, Normanno N, De Luca A, Mazzucato M, Celegato M, Colombatti A, Aldinucci D.

J Cell Biochem. 2013 May;114(5):1135-44. doi: 10.1002/jcb.24456.

PMID:
23192362
18.

Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy.

Kouodom MN, Boscutti G, Celegato M, Crisma M, Sitran S, Aldinucci D, Formaggio F, Ronconi L, Fregona D.

J Inorg Biochem. 2012 Dec;117:248-60. doi: 10.1016/j.jinorgbio.2012.07.001. Epub 2012 Jul 11.

PMID:
22877925
19.

Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics.

Kouodom MN, Ronconi L, Celegato M, Nardon C, Marchiò L, Dou QP, Aldinucci D, Formaggio F, Fregona D.

J Med Chem. 2012 Mar 8;55(5):2212-26. doi: 10.1021/jm201480u. Epub 2012 Feb 23.

PMID:
22309237
20.

The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment.

Aldinucci D, Gloghini A, Pinto A, Colombatti A, Carbone A.

Leuk Lymphoma. 2012 Feb;53(2):195-201. doi: 10.3109/10428194.2011.605190. Epub 2011 Aug 24. Review.

PMID:
21756027

Supplemental Content

Loading ...
Support Center